Drugs / BL22 immunotoxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00024115 | — | leukemia, lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL22 immunotoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024115 ↗ |
| Action | Deplete | “can locate tumor cells and kill them without harming normal cells” NCT00024115 ↗ |
| Modality | Protein / enzyme biologic | “recombinant BL22 immunotoxin” NCT00024115 ↗ |
| Route | Intravenous | “Patients receive recombinant BL22 immunotoxin IV over 30 minutes” NCT00024115 ↗ |